MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
60.66
+0.36
+0.60%
After Hours: 60.54 -0.12 -0.20% 19:58 02/20 EST
OPEN
60.62
PREV CLOSE
60.30
HIGH
60.93
LOW
59.65
VOLUME
9.60M
TURNOVER
--
52 WEEK HIGH
62.05
52 WEEK LOW
41.88
MARKET CAP
123.53B
P/E (TTM)
17.53
1D
5D
1M
3M
1Y
5Y
1D
From gold to crypto to AI, FOMO looms as a potential investing trap. Here's how to avoid it.
Seeking Alpha · 1d ago
Merck: Why Investors Should Remain Bullish Despite Patent Risks
Seeking Alpha · 1d ago
Down 25%, Should You Buy the Dip on Bristol Myers Squibb?
The Motley Fool · 1d ago
Pharmaceutical tariffs still in play despite Supreme Court ruling
Seeking Alpha · 2d ago
What Analysts Are Saying About Bristol-Myers Squibb Stock
Benzinga · 2d ago
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday
Benzinga · 2d ago
Dr. Reddy’s biosimilar for Bristol’s Orencia undergoes FDA review
Seeking Alpha · 2d ago
BMY’s Mavacamten Safety Extension Wraps Up, Sharpening the Long-Term Outlook in Hypertrophic Cardiomyopathy
TipRanks · 2d ago
More
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.